Research Article
BibTex RIS Cite

Mesane Kanseri Tedavisinde Kullanılmak Üzere CT/MR Uyumlu ve Ayarlanabilir Non-İnvaziv İntravezikal Yüksek Doz Hızlı Brakiterapi Aplikatörü Prototipinin Geliştirilmesi

Year 2020, Volume: 2 Issue: 1, 92 - 96, 15.06.2020

Abstract

Mesane kanseri tüm dünyada özellikle de ileri yaştaki insanları etkileyen önemli bir sağlık sorunudur. Hastaların birçoğu medikal nedenlerden dolayı cerrahi olamadıkları için ya da istemedikleri için organ koruyucu yaklaşımı tercih etmektedirler. Eksternal radyoterapi ve brakiterapi tedavileri organ koruyucu tedavinin bir parçası olup mevcut brakiterapi uygulamaları intertisyel olarak yapılmaktadır. Bu intertisyel uygulamanın ameliyethane şartlarında ve anestezi altında yapılması, uygulama sonrası hastanede kalış süresi ve maliyet önemli bir sorun olup oluşabilecek komplikasyonlara göre artış gösterebilmektedir. Bu çalışma ile anestezi ihtiyacını ortadan kaldırmak, iyileşme süresini kısaltmak, maliyeti düşürmek ve doğrudan ekonomik katkı sağlamak adına mesane kanseri tedavisinde kullanılmak üzere CT/MR Uyumlu ve Ayarlanabilir Non-İnvaziv İntravezikal Yüksek Doz Hızlı (HDR) Brakiterapi Aplikatörünün geliştirilmesi amaçlanmıştır.

Project Number

2018-2385

References

  • Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebrét T, et al. Guidelines on muscle-invasive and metastatic bladder cancer, 2014. https:// uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/.
  • Dutch guidelines bladder carcinoma version 1.0. http://www.oncoline.nl./ bladder carcinoma; 2009.
  • Koning CCE, Blank LECM, Koedooder C, van Os RM, van de Kar M, Jansen E, et al. Brachytherapy after external beam radiotherapy and limited surgery preserves bladders for patients with solitary pT1-pT3 bladder tumors. Ann Oncol 2012;23:2948-53.
  • Aluwini S, van Rooij PH, Kirkels WJ, Boormans JL, Kolkman-Deurloo IK, Wijnmaalen A. Bladder function preservation with brachytherapy, external beam radiation therapy, and limited surgery in bladder cancer patients: Longterm results. Int J Radiat Oncol Biol Phys 2014;88:611-7.
  • Pos F, Moonen L. Brachytherapy in the treatment of invasive bladder cancer. Semin Radiat Oncol 2005;15:49-54.
  • van Onna IEW, Oddens JR, Kok ET, van Moorselaar RJA, Ruud Bosch JLH, Battermann JJ. External beam radiation therapy followed by interstitial radiotherapy with iridium-192 for solitary bladder tumours: results of 111 treated patients. Eur Urol 2009;56:113-22.
  • Blank LECM, Koedooder K, van Os R, van de Kar M, van der Veen JH, Koning CCE. Results of bladder-conserving treatment, consisting of bracytherapy combined with limited surgery and external beam radiotherapy, for patients with solitary T1-T3 bladder tumors less than 5 cm in diameter. Int J Radiat Oncol Biol Phys 2007;69:45-48.
  • van der Steen-Banasik EM, Ploeg M, Witjes JA, van Rey FS, Idema JG, Heijbroek RP, et al. Brachytherapy versus cystectomy in solitary bladder cancer: a case control, multicentre, East-Netherlands study. Radiother Oncol 2009;93:3527.
  • Nieuwenhuizen JA, Pos F, Moonen LMF, Hart AAM, Horenblas S. Survival after bladder-preservation with brachytherapy versus radical cystectomy; a single institution experience. Eur Urol 2005;48:23945.
  • Bos M, Ordoñez Marmolejo R, Rasch CRN, Pieters BR. Bladder preservation with brachytherapy compared to cystectomy for T1T3 muscle-invasive bladder cancer: a systematic review. J Contemp Brachytherapy 2014;6:1919.

Development of CT/MR Compatible and Adjustable Non-Invaziv Intravesical High Dose Rate Brachytherapy Applicator Prototype for Treatment of Bladder Cancer

Year 2020, Volume: 2 Issue: 1, 92 - 96, 15.06.2020

Abstract

Bladder cancer is a major health problem affecting people all over the world, especially older people. Many of the patients prefer an organ-sparing approach because they cannot be operated for medical reasons or because they do not want to. External radiotherapy and brachytherapy treatments are part of the organ preservative treatment and the current brachytherapy applications are performed interstitially. This interventional procedure is performed under anesthesia in the operating room, hospital stay and cost is a significant problem and may increase according to the complications. The aim of this study is to develop CT/MR Compatible and Adjustable Non-Invaziv Intravesical High Dose Rate Brachytherapy Applicator for bladder cancer treatment in order to eliminate the need for anesthesia, shorten recovery time, reduce cost and provide a direct economic contribution.

Supporting Institution

Eskişehir Osmangazi Üniversitesi Bilimsel Araştırma Projeleri Birimi (Eskisehir Osmangazi University Scientific Research Projects Coordination Unit)

Project Number

2018-2385

Thanks

This study was supported by Eskisehir Osmangazi University Scientific Research Projects Coordination Unit (Project Number: 2018-2385).

References

  • Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebrét T, et al. Guidelines on muscle-invasive and metastatic bladder cancer, 2014. https:// uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/.
  • Dutch guidelines bladder carcinoma version 1.0. http://www.oncoline.nl./ bladder carcinoma; 2009.
  • Koning CCE, Blank LECM, Koedooder C, van Os RM, van de Kar M, Jansen E, et al. Brachytherapy after external beam radiotherapy and limited surgery preserves bladders for patients with solitary pT1-pT3 bladder tumors. Ann Oncol 2012;23:2948-53.
  • Aluwini S, van Rooij PH, Kirkels WJ, Boormans JL, Kolkman-Deurloo IK, Wijnmaalen A. Bladder function preservation with brachytherapy, external beam radiation therapy, and limited surgery in bladder cancer patients: Longterm results. Int J Radiat Oncol Biol Phys 2014;88:611-7.
  • Pos F, Moonen L. Brachytherapy in the treatment of invasive bladder cancer. Semin Radiat Oncol 2005;15:49-54.
  • van Onna IEW, Oddens JR, Kok ET, van Moorselaar RJA, Ruud Bosch JLH, Battermann JJ. External beam radiation therapy followed by interstitial radiotherapy with iridium-192 for solitary bladder tumours: results of 111 treated patients. Eur Urol 2009;56:113-22.
  • Blank LECM, Koedooder K, van Os R, van de Kar M, van der Veen JH, Koning CCE. Results of bladder-conserving treatment, consisting of bracytherapy combined with limited surgery and external beam radiotherapy, for patients with solitary T1-T3 bladder tumors less than 5 cm in diameter. Int J Radiat Oncol Biol Phys 2007;69:45-48.
  • van der Steen-Banasik EM, Ploeg M, Witjes JA, van Rey FS, Idema JG, Heijbroek RP, et al. Brachytherapy versus cystectomy in solitary bladder cancer: a case control, multicentre, East-Netherlands study. Radiother Oncol 2009;93:3527.
  • Nieuwenhuizen JA, Pos F, Moonen LMF, Hart AAM, Horenblas S. Survival after bladder-preservation with brachytherapy versus radical cystectomy; a single institution experience. Eur Urol 2005;48:23945.
  • Bos M, Ordoñez Marmolejo R, Rasch CRN, Pieters BR. Bladder preservation with brachytherapy compared to cystectomy for T1T3 muscle-invasive bladder cancer: a systematic review. J Contemp Brachytherapy 2014;6:1919.
There are 10 citations in total.

Details

Primary Language English
Subjects Clinical Sciences
Journal Section Research Articles
Authors

Alaattin Özen

Ata Özen

Kerem Duruer This is me

Project Number 2018-2385
Publication Date June 15, 2020
Published in Issue Year 2020 Volume: 2 Issue: 1

Cite

APA Özen, A., Özen, A., & Duruer, K. (2020). Development of CT/MR Compatible and Adjustable Non-Invaziv Intravesical High Dose Rate Brachytherapy Applicator Prototype for Treatment of Bladder Cancer. Journal of Medical Innovation and Technology, 2(1), 92-96.
AMA Özen A, Özen A, Duruer K. Development of CT/MR Compatible and Adjustable Non-Invaziv Intravesical High Dose Rate Brachytherapy Applicator Prototype for Treatment of Bladder Cancer. Journal of Medical Innovation and Technology. June 2020;2(1):92-96.
Chicago Özen, Alaattin, Ata Özen, and Kerem Duruer. “Development of CT/MR Compatible and Adjustable Non-Invaziv Intravesical High Dose Rate Brachytherapy Applicator Prototype for Treatment of Bladder Cancer”. Journal of Medical Innovation and Technology 2, no. 1 (June 2020): 92-96.
EndNote Özen A, Özen A, Duruer K (June 1, 2020) Development of CT/MR Compatible and Adjustable Non-Invaziv Intravesical High Dose Rate Brachytherapy Applicator Prototype for Treatment of Bladder Cancer. Journal of Medical Innovation and Technology 2 1 92–96.
IEEE A. Özen, A. Özen, and K. Duruer, “Development of CT/MR Compatible and Adjustable Non-Invaziv Intravesical High Dose Rate Brachytherapy Applicator Prototype for Treatment of Bladder Cancer”, Journal of Medical Innovation and Technology, vol. 2, no. 1, pp. 92–96, 2020.
ISNAD Özen, Alaattin et al. “Development of CT/MR Compatible and Adjustable Non-Invaziv Intravesical High Dose Rate Brachytherapy Applicator Prototype for Treatment of Bladder Cancer”. Journal of Medical Innovation and Technology 2/1 (June 2020), 92-96.
JAMA Özen A, Özen A, Duruer K. Development of CT/MR Compatible and Adjustable Non-Invaziv Intravesical High Dose Rate Brachytherapy Applicator Prototype for Treatment of Bladder Cancer. Journal of Medical Innovation and Technology. 2020;2:92–96.
MLA Özen, Alaattin et al. “Development of CT/MR Compatible and Adjustable Non-Invaziv Intravesical High Dose Rate Brachytherapy Applicator Prototype for Treatment of Bladder Cancer”. Journal of Medical Innovation and Technology, vol. 2, no. 1, 2020, pp. 92-96.
Vancouver Özen A, Özen A, Duruer K. Development of CT/MR Compatible and Adjustable Non-Invaziv Intravesical High Dose Rate Brachytherapy Applicator Prototype for Treatment of Bladder Cancer. Journal of Medical Innovation and Technology. 2020;2(1):92-6.